Multiple Lesions at Different Stages of Pyoderma Gangrenosum in a Crohn’s Disease Patient

Heng Zhang, Yifang Sun, Kun Li, Jianzhong Zhang, Xue Chen

Department of Dermatology, Peking University People’s Hospital, Beijing, 100044, People’s Republic of China

Correspondence: Xue Chen, Department of Dermatology, Peking University People’s Hospital, # 11. Xizhimen South St, Beijing, 100044, People’s Republic of China, Tel +86 10 88325472, Fax +86 10 88325474, Email rmnkxx@163.com

Abstract: Pyoderma gangrenosum (PG) is an inflammatory dermatosis characterized by the rapid progression of a painful, necrolytic ulcer with an irregular and undermined border. The prevalence of PG in patients with Crohn’s disease (CD) has been estimated to be 0.7%. Here, we report a case that presented various painful skin lesions, including erythema, vesicles, plaques, and ulcers, one week before the fourth infliximab infusion for CD. PG was diagnosed and the lesions subsided after a 390-mg ustekinumab infusion for one month. It suggests that different lesions of PG may occur concomitantly in CD patients, and the therapy should be re-evaluated on time.

Keywords: pyoderma gangrenosum, Crohn’s disease, cutaneous manifestation

Introduction

Pyoderma gangrenosum (PG) was first described in 1908 as a “geometric phagedena” (phagédénisme géométrique) and was later redefined as PG in 1930.1 It is an inflammatory dermatosis characterized by the rapid progression of a painful, necrolytic ulcer with an irregular, undermined border. The early stages of pyoderma gangrenosum may present as pustules and nodules that may progress to ulcers. The pathogenesis of PG remains unclear. Pathophysiology is believed to be related to the exaggerated recruitment of neutrophils to the dermis, which is a typical pathological feature of PG. PG is usually a diagnosis of exclusion; however, recently diagnostic criteria for PG have been proposed.1

PG is associated with systemic disorders, such as rheumatoid arthritis, hematological malignancies, and inflammatory bowel disease (IBD) in about half of the cases.2,3 Almost one-third of patients with PG have an underlying IBD and the prevalence of PG in patients with Crohn’s disease (CD) has been estimated to be 0.7%.4 Here, we report a patient with CD presented with various stages of lesions of PG.

Case Report

A 29-year-old man presented with various painful skin lesions, including erythema, vesicle, plaques, and ulcers, one week before the fourth infliximab infusion for moderately active CD. Physical examination showed multiple erythematous papules/plaques covered with crust on the scalp and face ranging from 0.5 to 1.5 cm. An erythematous papulovesicle was on the abdomen, and an oval, 0.5cm-sized, erythematous ulcer was on the calf. In addition, a single oval, 1cm-sized, sharply demarcated ulcer is located on the penis (Figure 1). Skin biopsies revealed epidermal acanthosis and a lichenoid infiltration of lymphocytes in the superficial dermis with dermal edema (the papule on the abdomen) and a dense polymorphic inflammatory dermal infiltrate, very rich in neutrophils, compatible with PG (the ulcer on the calf) (Figure 2). Laboratory and radiologic tests were negative for infection, vasculitis, and malignancy. Bone marrow biopsy was normal. Tissue cultures grew neither bacteria nor fungi. The patient was diagnosed with PG, and because of inadequate response to infliximab, a ustekinumab infusion was given. The lesions gradually subsided after a 390-mg ustekinumab infusion for one month.
PG is a rare neutrophilic dermatosis with an estimated incidence of 3–10 cases per million per year.\textsuperscript{2} It occurs most commonly in individuals 20–60 years old, with the average age of onset at 44 years old.\textsuperscript{3,5} Approximately 50% of patients have other associated conditions such as IBD, arthritis, and hematological malignancies (acute myelogenous leukemia, myelodysplasia, and IgA monoclonal gammopathies).\textsuperscript{5–8} PG has five widely recognized subtypes-ulcerative PG, bullous PG, vegetative PG, pustular PG, and peristomal PG.\textsuperscript{9} The most common morphologic variant is ulcerative PG.\textsuperscript{10}

Ulcerative PG typically presents with an inflammatory and tender nodule or pustule that rapidly expands into an ulcer. The ulcer was always demonstrated with an undermined violaceous border and a purulent base. The disease recovers slowly, and the healing of lesions may result in disfiguring cribiform scar formation. PG is a diagnosis of exclusion.

**Figure 1** (A–C) multiple erythematous papules/plaques covered with crust on the scalp and face ranging from 0.5 to 1.5 cm. (D) an erythematous papulovesicle on the abdomen. (E) single oval, 1 cm-sized, sharply demarcated ulcer located on the penis. (F) an erythematous ulcer on the right calf.

**Figure 2** (A) an epidermal acanthosis and a lichenoid lymphocyte infiltrate in the superficial dermis with dermal edema (the papulovesicle on the abdomen, HE, ×100), (B) a dense polymorphic inflammatory dermal infiltrate, very rich in neutrophils (the ulcer on the calf, HE, ×100).
Clinical, histological, and laboratory findings are nonspecific and cannot be used alone for a definitive diagnosis. Although widespread validated diagnostic criteria are lacking for PG, practical criteria have been suggested. We finally excluded vasculitis, thrombophilic conditions, malignancies, infections, and other inflammatory diseases through a series of laboratory tests and radiological examinations.

CD is an inflammatory condition of the gastrointestinal tract and can affect other organs, including the skin, eyes, liver, and joints. Cutaneous extraintestinal manifestations are currently divided into four categories: (1) disease-specific lesions, (2) reactive lesions, (3) associated conditions, and (4) therapy-related lesions. Disease-specific lesions that are seen only in CD, including perianal fissures/fistulae and metastatic CD, are caused by the direct involvement of the skin by a pathologic mechanism identical to the underlying CD. Erythema nodosum (EN) and pyoderma gangrenosum are common cutaneous manifestations of reactive lesions, which are induced by cross antigenicity between the integument and gut mucosa without exhibiting the exact pathologic features of the IBD. As therapeutic options for IBD expand, some investigators have proposed a fourth category of cutaneous extraintestinal manifestations-therapy-related lesions.

The histopathologic findings of PG are not specific, and the primary objective in obtaining a biopsy specimen is to rule out other causes of ulceration. Skin biopsy specimens taken from the erythematous regions adjacent to ulcers may show the disruption or necrosis of dermal or panniculic blood vessels (with lymphocytes as the primary inflammatory cells). Classical histopathological findings demonstrated mixed cellular inflammation with neutrophil predominance in skin biopsy specimens of necrotic, undermined ulcer border. In this case, the skin biopsy of the ulcer showed typical features of neutrophil infiltration. In contrast, that of the papulovesicle demonstrated a lichenoid lymphocyte infiltrate in the superficial dermis with dermal edema, indicating that different stages of PG lesions revealed different histopathological manifestations.

Systemic corticosteroids and immunosuppressive agents are the main treatment for PG. Biologics and small-molecule drugs are emerging. In addition, treating the underlying disease may be helpful. Infliximab-Tumor Necrosis Factor (TNF) antagonists have shown a more remarkable improvement for PG. Other biologics, such as Tocilizumab, Ustekinumab, Vedolizumab, anakinra, canakinumab, and small-molecule drugs, including tofacitinib and apremilast, have been reported to be effective in some small sample cases.

**Conclusion**

Here, we present an unusual case of various stages of lesions of PG concomitantly in a Crohn’s disease patient one week before the fourth infliximab infusion and the lesions gradually subsided after taking ustekinumab for one month. It suggests that various painful skin lesions, including erythema, vesicles, plaques, and ulcers, might be the manifestation of PG and the therapy should be re-evaluated.

**Ethics and Consent Statements**

Written informed consent was provided by the patient to have the case details and any accompanying images published. Institutional approval was not required to publish the case details.

**Funding**

There is no funding to report.

**Disclosure**

The authors report no conflicts of interest in this work.
References

1. Maverakis E, Ma C, Shinkai K, et al. Diagnostic criteria of ulcerative pyoderma gangrenosum: a delphi consensus of international Experts. JAMA Dermat 2018;154(4):461–466. doi:10.1001/jamadermatol.2017.5980
2. Ruocco E, Sangiuliano S, Gravina A, Miranda A, Nicoletti G. Pyoderma gangrenosum: an updated review. J Eur Acad Dermatol Venereol. 2009;23(9):1008–1017. doi:10.1111/j.1468-3083.2009.03199.x
3. Binus A, Qureshi A, Li V, Winterfield L. Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients. Br J Dermatol. 2011;165(s):1244–1250. doi:10.1111/j.1365-2133.2011.10565.x
4. Thrash B, Patel M, Shah K, Boland C, Menter A. Cutaneous manifestations of gastrointestinal disease: part II. J Am Acad Dermatol. 2013;68(2):211.e211–233; quiz 244–216.
5. Bennett M, Jackson J, Jorizzo J, Fleischer A, White W, Callen J. Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine. 2000;79(1):37–46. doi:10.1097/00005792-200001000-00004
6. Crowson A, Mihm M, Magro C. Pyoderma gangrenosum: a review. J Cutan Pathol. 2003;30(2):97–107. doi:10.1034/j.1600-0560.2003.00024.x
7. Platzer K, Kostner L, Vujic I, et al. Clinical characteristics and treatment outcomes of 36 pyoderma gangrenosum patients - a retrospective, single institution observation. J Eur Acad Dermatol Venereol. 2019;33(12):e474–e475. doi:10.1111/jdv.15803
8. Thrash B, Patel M, Shah K, Boland C, Menter A. Cutaneous manifestations of gastrointestinal disease: part II. J Am Acad Dermatol. 2013;68(2):211.e211–233; quiz 244–216.
9. Bennett M, Jackson J, Jorizzo J, Fleischer A, White W, Callen J. Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine. 2000;79(1):37–46. doi:10.1097/00005792-200001000-00004
10. Ahn C, Negus D, Huang W. Pyoderma gangrenosum: a review of pathogenesis and treatment. J Am Acad Dermatol. 2012;13(3):191–211. doi:10.2165/11595240-000000000-00000
11. Su W, Davis M, Weenig R, Powell F, Perry H. Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. Int J Dermatol. 2004;43(11):790–800. doi:10.1111/j.1365-4632.2004.02128.x
12. Xaviere RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448(7152):427–434. doi:10.1038/nature06005
13. Alavi A, French L, Davis M, Brassard A, Kirsner R. Pyoderma gangrenosum: an update on pathophysiology, diagnosis and treatment. Am J Clin Dermatol. 2017;18(3):355–372. doi:10.1007/s40257-017-0251-7
14. Ashchyan HJ, Nelson CA, Stephen S, James WD, Micheletti RG, Rosenbach M. Neutrophilic dermatoses: pyoderma gangrenosum and other bowel- and arthritis-associated neutrophilic dermatoses. J Am Acad Dermatol. 2018;79(6):1009–1022. doi:10.1016/j.jaad.2017.11.063
15. Ahn C, Negus D, Huang W. Pyoderma gangrenosum: a review of pathogenesis and treatment. Expert Rev Clin Immunol. 2018;14(3):225–233. doi:10.1080/1744666X.2018.1438269
16. Wenzel J, Gerdsen R, Philipp-Dormston W, Bieber T, Uerlich M. Topical treatment of pyoderma gangraenosum. Dermatology. 2002;205(3):221–223. doi:10.1159/000065843
17. Brooklyn T, Dunnill M, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006;55(4):505–509. doi:10.1136/gut.2005.074815
18. Ben Abdallah H, Fogh K, Bech R. Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: a semi-systematic review. Int Wound J. 2019;16(2):511–521. doi:10.1111/iwj.13067
19. Lee W, Choi Y, Yoo W. Use of tocilizumab in a patient with pyoderma gangrenosum and rheumatoid arthritis. J Eur Acad Dermatol Venereol. 2017;31(2):e75–e77. doi:10.1111/jdv.13736
20. Nunes G, Patita M, Fernandes V. Refractory Pyoderma gangrenosum in a patient with Crohn’s disease: complete response to ustekinumab. J Crohns Colitis. 2019;13(6):812–813. doi:10.1093/ecco-jcc/jjy200
21. Dubinsky M, Cross R, Sandborn W, et al. Extraintestinal manifestations in vedolizumab and anti-TNF-treated patients with inflammatory bowel disease. Inflamm Bowel Dis. 2018;24(9):1786–1882. doi:10.1093/ibd/izy065
22. Ben Abdallah H, Fogh K, Vestergaard C, Bech R. Pyoderma gangrenosum and interleukin inhibitors: a semi-systematic review. Dermatology. 2022;238(4):785–792. doi:10.1159/000519320
23. Kochar B, Herfarth N, Mamie C, Navarini A, Scharl M, Herfarth H. Tofacitinib for the treatment of pyoderma gangrenosum. Clin Gastroenterol Hepatol. 2019;17(5):991–993. doi:10.1016/j.cgh.2018.10.047
24. Vemerno M, Ribaldone D, Cariti C, et al. Dual-targeted therapy with apremilast and vedolizumab in pyoderma gangrenosum associated with Crohn’s disease. J Dermatol. 2020;47(6):e216–e217. doi:10.1111/1346-8138.15283

Clinical, Cosmetic and Investigational Dermatology
Publish your work in this journal

Clinical, Cosmetic and Investigational Dermatology is an international, peer-reviewed, open access, online journal that focuses on the latest clinical and experimental research in all aspects of skin disease and cosmetic interventions. This journal is indexed on CAS. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/clinical-cosmetic-and-investigational-dermatology-journal